Nov. 11 at 8:14 PM
$QNRX Quoin filed U.S. and international patent applications in March 2025 for novel topical rapamycin formulations using Invisicare. These cover treatments for the mentioned rare diseases, but specific application numbers are not yet publicly available (as patent applications typically publish after 18 months). Additional filings were noted in March 2025 for broader rare skin disease applications.
$PVLA : Palvella Therapeutics (PVLA) - QTORIN™ Rapamycin
Palvella’s QTORIN™ platform is a patented anhydrous gel system designed for topical delivery of rapamycin, an mTOR inhibitor, to treat rare genetic skin conditions like Pachyonychia Congenita, microcystic lymphatic malformations, and potentially others. The technology emphasizes stable, high-concentration anhydrous formulations (e.g., 3.9% rapamycin) that enable targeted skin penetration without significant systemic exposure, which is critical for chronic use in sensitive populations.
